The National Taiwan University Hospital is a medical facility located in the Zhongzheng District of Taipei, Taiwan. It started operations under Japanese rule in Daitōtei on 18 June 1895, and moved to its present location in 1898.

There are 2,400 beds in National Taiwan University Hospital.

During the past decade, National Taiwan University Hospital conducted 1228 clinical trials. In the 10-year time frame, 1228 clinical trials started and 252 clinical trials were completed, i.e. on average, 20.5% percent of trials that started reached the finish line to date. In the past 5 years, 617 clinical trials started and 176 clinical trials were completed. i.e. 28.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Taiwan University Hospital" #1 sponsor was "National Taiwan University Hospital" with 1149 trials, followed by "Pfizer" with 71 trials sponsored, "Janssen Research & Development, LLC" with 45 trials sponsored, "Boehringer Ingelheim" with 36 trials sponsored and "Hoffmann-La Roche" with 36 trials sponsored. Other sponsors include 687 different institutions and companies that sponsored additional 296 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Taiwan University Hospital" #1 collaborator was "National Science Council, Taiwan" with 80 trials as a collaborator, "National Taiwan University Hospital" with 41 trials as a collaborator, "National Cheng-Kung University Hospital" with 30 trials as a collaborator, "Chang Gung Memorial Hospital" with 28 trials as a collaborator and "Taipei Veterans General Hospital, Taiwan" with 23 trials as a collaborator. Other collaborators include 631 different institutions and companies that were collaborators in the rest 301 trials.

According to Clinical.Site data, the most researched conditions in "National Taiwan University Hospital" are "Hepatocellular Carcinoma" (35 trials), "Breast Cancer" (28 trials), "Lung Cancer" (23 trials), "Stroke" (22 trials) and "Gastric Cancer" (21 trials). Many other conditions were trialed in "National Taiwan University Hospital" in a lesser frequency.

Most popular intervention types in "National Taiwan University Hospital" are "Drug" (934 trials), "Other" (226 trials), "Device" (132 trials), "Procedure" (123 trials) and "Biological" (119 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (217 trials), "Pembrolizumab" (29 trials), "Carboplatin" (26 trials), "Cisplatin" (25 trials) and "Paclitaxel" (21 trials). Other intervention names were less common.

The vast majority of trials in "National Taiwan University Hospital" are 1833 trials for "All" genders, 132 trials for "Female" genders and 63 trials for "Male" genders.

Currently, there are 592 active trials in "National Taiwan University Hospital". 18 are not yet recruiting, 358 are recruiting, 200 are Active, not recruiting, and 16 are Enrolling by invitation. In total, there were 690 completed trials in National Taiwan University Hospital, 4 suspended trials, and 105 terminated clinical trials to date.

Out of the total trials that were conducted in National Taiwan University Hospital, 163 "Phase 1" clinical trials were conducted, 312 "Phase 2" clinical trials and 436 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 126 trials, and there were also 415 trials that are defined as “Not Applicable".